Literature DB >> 22054879

Pathology of lung cancer.

William D Travis1.   

Abstract

This article reviews current concepts in pathologic classification of lung cancer based on the 2004 World Health Organization classification of lung tumors and the 2011 International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification of lung adenocarcinoma. Preinvasive lesions are discussed. The major changes in lung disease diagnosis affected by the IASLC/ATS/ERS classification are presented. For adenocarcinomas diagnosed in small biopsies, specific terminology and diagnostic criteria are proposed along with recommendations for strategic management of tissue and EGFR mutation testing in patients with advanced adenocarcinoma. Histologic criteria are also presented for other tumors. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22054879     DOI: 10.1016/j.ccm.2011.08.005

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  207 in total

1.  Quantifying the expression of tumor marker genes in lung squamous cell cancer with RNA sequencing.

Authors:  Lin Wang; Cheng Zhan; Yongxing Zhang; Jun Ma; Junjie Xi; Wei Jiang; Yu Shi; Qun Wang
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer.

Authors:  Xu-Yong Lin; Xiu-Peng Zhang; Jun-Hua Wu; Xue-Shan Qiu; En-Hua Wang
Journal:  Tumour Biol       Date:  2014-03-29

3.  IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance.

Authors:  Xueyan Zhang; Jiayuan Sun; Huimin Wang; Yuqing Lou; Yanwei Zhang; Huifang Sha; Jiuxian Feng; Baohui Han
Journal:  Tumour Biol       Date:  2013-08-29

Review 4.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

5.  Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.

Authors:  Showkat A Malik; Mosin S Khan; Majeed Dar; Mahboob Ul Hussain; Mohammad A Shah; Sheikh M Shafi; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2017-04-22       Impact factor: 3.201

6.  LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.

Authors:  Linmei Wang; Xueqin Shang; Qingqing Feng
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

7.  The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells.

Authors:  Yang Liu; Liang Wang; Xu-Yong Lin; Jian Wang; Juan-Han Yu; Yuan Miao; En-Hua Wang
Journal:  Tumour Biol       Date:  2013-02-20

8.  The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.

Authors:  Wan Ling Tan; Quan-Sing Ng
Journal:  Transl Lung Cancer Res       Date:  2016-02

9.  Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?

Authors:  Giuseppe Lo Russo; Claudia Proto; Marina Chiara Garassino
Journal:  Transl Lung Cancer Res       Date:  2016-02

10.  Prognostic significance of CT-emphysema score in patients with advanced squamous cell lung cancer.

Authors:  Young Saing Kim; Eun Young Kim; Hee Kyung Ahn; Eun Kyung Cho; Yu Mi Jeong; Jeong Ho Kim
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.